The world of Kedrion Biopharma at a glance:
discover the latest
up-to-date news.

All news.
The Fifth John Gorman Lectureship at the “Birth 2022 Congress”
These Conferences in Transfusion Medicine are made possible thanks to the unconditional support of Kedrion Biopharma
Read all
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Read all
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1
Read all